Table 3

Effect of immune inhibitors on susceptibility of third-instar gypsy moth larvae reared without antibiotics to B. thuringiensis toxin (MVPII; 20 μg).

Total Mortality (mean proportion ± SE)

Compound added to

B. thuringiensis toxin (MVPII)

Compound activity

Compound concentration

N

without

B. thuringiensis

with

B. thuringiensis

Significance

(p-value) of

rank analysis


B. thuringiensis toxin control

48

0.06 ± 0.02

0.92 ± 0.15 a

Acetylsalicylic acid

Eicosanoid inhibitor (COX)

100 μg

36

0.00 ± 0.00

0.81 ± 0.16 ab

0.0396

Dexamethasone

Eicosanoid inhibitor (PLA2)

100 μg

24

0.00 ± 0.00

0.79 ± 0.19 ab

0.4519

Indomethacin

Eicosanoid inhibitor (COX)

10 μg

48

0.04 ± 0.04

0.83 ± 0.14 ab

0.0056

Esculetin

Eicosanoid inhibitor (LOX)

100 μg

24

0.00 ± 0.00

0.83 ± 0.18 ab

0.9757

Piroxicam

Eicosanoid inhibitor (COX)

100 μg

36

0.04 ± 0.02

0.94 ± 0.18 a

0.2417

Glutathione

Nitric oxide scavenger, phenoloxidase inhibitor

1.2 μg

36

0.02 ± 0.02

0.72 ± 0.14 ab

0.0154

N-acetyl cysteine

Reactive oxygen scavenger

100 mM

36

0.03 ± 0.01

0.86 ± 0.15 a

0.0286

Phenylthiourea

Nitric oxide scavenger, phenoloxidase inhibitor

75 mM

36

0.03 ± 0.03

0.81 ± 0.15 ab

0.3382

S-methyl-L-thiocitrulline

Nitric oxide scavenger

100 mM

36

0.03 ± 0.02

0.83 ± 0.15 ab

0.0245

Tannic acid

Phenoloxidase inhibitor

100 μg

24

0.00 ± 0.00

0.79 ± 0.19 ab

0.2740

S-nitroso-N-acetyl-l, l-penicillamine

Nitric oxide donor

100 mM

36

0.00 ± 0.00

0.94 ± 0.18 a

0.4409


The value N refers to the total number of larvae tested per treatment. There were no effects by these compounds without B. thuringiensis. Log-rank analysis was used to compare larval survival for each concentration of inhibitor, treatments with a p-value < 0.05 were considered significantly different from Bt toxin alone. Mean mortality values followed by the same letter do not differ significantly from each other.

Broderick et al. BMC Microbiology 2010 10:129   doi:10.1186/1471-2180-10-129

Open Data